[HTML] plos.org

[HTML][HTML] Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLoS …, 2021 - journals.plos.org
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
被引用次数：44 相关文章

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - Plos …, 2021 - europepmc.org
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLOS …, 2021 - ideas.repec.org
Background: A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
[PDF] archive.org

[PDF][PDF] Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLoS …, 2021 - scholar.archive.org
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith… - PLOS …, 2021 - article.publish4promo.com
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLoS Medicine, 2021 - go.gale.com
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith… - PLoS …, 2021 - pubmed.ncbi.nlm.nih.gov
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith… - PLOS …, 2021 - econpapers.repec.org
Background: A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
[HTML] nih.gov

[HTML][HTML] Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLoS …, 2021 - ncbi.nlm.nih.gov
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.

JJ Kim, KT Simms, J Killen, MA Smith… - PLoS …, 2021 - search.ebscohost.com
Abstract < bold> Background: </bold> A nonavalent human papillomavirus (HPV)
vaccine has been licensed for use in women and men up to age 45 years in the United …